Clinical Trials Using AXL Inhibitor BGB324
Clinical trials are research studies that involve people. The clinical trials on this list are studying AXL Inhibitor BGB324. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Bemcentinib in Treating Patients with Recurrent Glioblastoma Undergoing Surgery
This phase I trial studies how well bemcentinib works in treating patients with glioblastoma that has come back who are undergoing surgery. Bemcentinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 3 locations
Bemcentinib with Nab-Paclitaxel, Gemcitabine, and Cisplatin in Treating Patients with Metastatic or Recurrent Pancreatic Cancer
This phase Ib / II trial studies how well bemcentinib in combination with nab-paclitaxel, gemcitabine, and cisplatin work in treating patients with pancreatic cancer that has spread to other places in the body or that has come back. Bemcentinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as nab-paclitaxel, gemcitabine, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bemcentinib with nab-paclitaxel, gemcitabine, and cisplatin may work better in treating patients with pancreatic cancer.
Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas
A Phase Ib / II Multicenter Open-label Study of BGB324 in Patients With AML or MDS
A Phase Ib / II multicentre open label study of BGb324 as a single agent in patients with AML or MDS or in a combination with cytarabine and decitabine in AML patients. BGB324 is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is overexpressed in up to half of AML cases.
Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa
A Study of BGB324 in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
A Phase I / 2 multi-center open-label study of BGB324 in combination with erlotinib in patients with Stage IIIb or Stage IV non-small cell lung cancer. BGB324 is a potent selective small molecule inhibitor of Axl, a surface membrane protein kinase receptor which is connected with poor prognosis and acquired resistance to therapy.
Location: See Clinical Trials.gov